Skip to content
S927Senate2023-2024 SessionSame asA9075

Cover Genetic Cancer Screening

Official title

“Requires health insurance policies to cover comprehensive genetic screening for ovarian and prostate cancers”

Sponsor Roxanne J. PersaudSD-19+2 co-sponsorsAffects Finance
Status
In Senate Committee
Insurance
Impact
8/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires health insurance policies in New York to fully cover comprehensive genetic and FDA-approved biomarker testing for ovarian and prostate cancers, including for family members, with no deductibles or coinsurance.

Why it matters

  1. Eliminates financial barriers. By mandating that insurers cover all costs for genetic and biomarker testing related to ovarian and prostate cancers, the bill removes out-of-pocket expenses like deductibles and coinsurance, making advanced diagnostics accessible regardless of income.

  2. Expands genetic testing to family members. Coverage is not limited to the patient, but also includes genetic screening for family members, which could help identify others at risk and enable earlier interventions or preventive care across families.

  3. Protects against genetic discrimination. The bill explicitly prohibits insurers from using genetic test results to deny or limit coverage for family members who carry cancer-related mutations, reducing fears about negative insurance consequences from getting tested.

  4. Supports personalized treatment. By ensuring access to comprehensive genetic and FDA-approved biomarker testing both before and after diagnosis, the law enables more precise and effective treatment planning, potentially improving outcomes for those with or at risk for these cancers.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Cover Genetic Cancer Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Roxanne J. Persaud

Senator · Senate District 19

Chair, Social Services

History

  1. Referred to insurance
  2. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A9075Assembly

Require Insurer Cancer Gene Tests

In Assembly Committee · Insurance · Sponsor Amanda Septimo

Impact 8 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

927

2023-2024 Regular Sessions

IN SENATE

January 9, 2023

Introduced by Sen. PERSAUD -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "Ana Lucia act".

§ 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C) (i) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic counselor. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

(ii) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 3. Paragraph 11-a of subsection (l) of section 3221 of the insurance law is amended by adding a new subparagraph (C) to read as follows:

(C)(i) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic coun-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD00460-01-3

selor. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

(ii) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer.

§ 4. Subsection (z-1) of section 4303 of the insurance law is amended by adding a new paragraph 3 to read as follows:

(3)(A) Such policy shall provide additional full coverage for comprehensive genetic testing and FDA approved testing based on family or person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic counselor.

(B) All costs associated with such additional full coverage shall not be subject to annual deductibles and coinsurance but shall be borne solely by the insurer. Such coverage shall also be provided after the patient's initial diagnosis. Patients need to know if they carry the genetic or inheritance mutation, which can help to determine possible treatments. Genetic screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family members that carry the genetic or inheritance mutation for insurance coverage purposes.

§ 5. This act shall take effect on the sixtieth day after it shall have become a law and shall apply to all policies, contracts and certificates issued, renewed, modified, altered or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers

Purpose

Requires health insurance policies to cover comprehensive genetic screening for ovarian and prostate cancers

Summary of provisions

Section I states that this act shall be cited as the "Ana Lucia Act."

Section II Paragraph 11-a of subsection (i) of section 3216 law is amended by adding a new subparagraph (C)(i) to provide additional full coverage for comprehensive genetic testing and FDA-approved testing based on family or person's history when recommended by a board-certi- fied geneticist or a board-certified genetic counselor.

Section III Paragraph 11-a of subsection (1) of section 3221 of the insurance law is amended by adding a new subparagraph (C) to provide additional full coverage for the comprehensive genetic testing and FDA approved testing based on family or person's history when recommended by a board-certified geneticist or a board-certified genetic counselor.

Section IV Subsection (z-1) of section 4303 of the insurance law is amended by adding a new paragraph 3(A) to provide additional full cover- age for comprehensive genetic testing and FDA-approved testing based on family or person's history when recommended by a board-certified geneti- cist or a board-certified genetic counselor.

Section V provides for the effective date of the sixtieth day after it shall become a law.

Justification

This legislation mandates that insurance companies cover the costs of genetic and FDA-approved biomarker testing for ovarian and prostate cancer, which could lead to early detection, and in some cases, prevents some of the most common and life-threatening cancers such as breast, prostate, ovarian, colon, and lung cancers. According to the American Cancer Society, 1 in 41 men will die from prostate cancer, hence why it is "the second leading cause of cancer death in American men, behind lung cancer." In 2021, there are approximately 248,530 new cases of prostate cancer and roughly 34,130 deaths.

According to the National Center for Biotechnology Information, "ovarian cancer is the ninth leading cause of cancer to women, but the fifth leading cause of all cancer-related. deaths." In 2009, There were 21,550 new cases and 14,600 deaths were estimated. 1 in 78 American. women will be diagnosed with ovarian cancer during their lifetime.

Ovarian cancer is difficult to detect, particularly in the early stage; its symptoms mimic others such as bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, fatigue, upset stomach or heart- burn, back pain, pain during sex, constipation, menstrual changes, feel- ing the need to urinate instantly or often. The ovaries are small, shaped like almonds, located deep within the abdominal cavity; one on each side of the uterus which makes it hard to test for ovarian cancer. Currently, there is no blood " work to detect ovarian cancer.

Although we rely on the CA 125 to monitor women that are being treated for ovarian cancer, it is not a helpful screening test for cancer. An elevated CA 125 does not automatically mean one has cancer. A high level of CA 125 can occur due to many non-cancerous conditions. For instance, roughly of women with elevated CA 125 levels have ovarian cancer" Up to 20% of ovarian cancer patients do not have an elevated CA 125 MedicineN- et).

Legislative history

S2021-2022 S105 A Referred to Insurance

2020:S105 Referred to Insurance

Fiscal impact on the state

To be determined.

Effective date

This act shall take effect on the sixtieth day after it shall have become law

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.